Mivavotinib Citrate

**Semantic type:** Pharmacologic Substance

**Definition:** An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.

**Synonyms:** - 6-(((1R,2S)-2-Aminocyclohexyl)Amino)-7-Fluoro-1,2-Dihydro-4-(1-Methyl-1H-Pyrazol-4-yl)-3H-Pyrrolo(3,4-C)Pyridin-3-One, 2-Hydroxypropane-1,2,3-Tricarboxylate (1:1) - MIVAVOTINIB CITRATE - TAK-659 - TAK659